证券代码：300677 证券简称：英科医疗 公告编号：2025-066 英科医疗科技股份有限公司 出席本次业绩说明会的人员有：公司总经理陈琼女士，独立董事 吴晓辉先生、贾建军先生及向静女士，董事会秘书兼财务总监冯杰女 士。具体以当天实际参会人员为准。 为充分尊重投资者、提升交流的针对性，现就公司 2024 年度暨 2025 年第一季度业绩说明会提前向投资者公开征集问题，广泛听取 投资者的意见和建议。投资者可于业绩说明会开始前登录中国证券 报·中证网"路演中心"，进入公司业绩说明会页面进行提问。 敬请广大投资者提交您所关注的问题，便于公司在业绩说明会上 对投资者普遍关注的问题进行回答，提升此次业绩说明会的针对性。 此次活动交流期间，投资者仍可登陆活动界面进行互动提问。 欢迎广大投资者积极参与！ 特此公告。 英科医疗科技股份有限公司 关于举行 2024 年度暨 2025 年第一季度业绩说明会 的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）已分别于 2025 年 4 月 24 日、2025 年 4 月 29 日在巨潮资 ...

Core Viewpoint - The event "New Quality Shandong Brands Build the Future" highlighted the importance of ESG (Environmental, Social, and Governance) strategies in enhancing brand value and sustainable development, with Yingke Medical being recognized as an exemplary case for its ESG efforts in Shandong [2][4]. Group 1: ESG Strategy - ESG strategies are integral to brand strategy and are crucial for measuring a company's sustainable development capabilities, gaining significant attention from businesses and investors [4]. - Yingke Medical aims to improve its MSCI ESG rating from BB to BBB and has set clear ESG goals aligned with its business model and core values, focusing on energy sustainability, employee satisfaction, and board diversity [4][6]. Group 2: Environmental Initiatives - In 2024, Yingke Medical plans to enhance its technology and production processes to improve product quality while adhering to sustainable development principles, aiming to reduce environmental impact and support national carbon neutrality goals [6]. - The company is implementing green transportation and energy-saving measures to create a sustainable operational environment [6]. Group 3: Social Contributions - Yingke Medical sponsored the "Yingke Cup" fencing competition, attracting over 300 young athletes, and initiated a charity event to provide winter clothing for 667 underprivileged families [6]. - The Yingke Charity Foundation conducted research and donation activities in Yunnan, providing wheelchairs and walking aids to improve mobility for disabled individuals in remote areas [6]. Group 4: Corporate Governance - Yingke Medical emphasizes employee development through a comprehensive talent management system, fostering a diverse and attractive workplace [7]. - The company organizes various employee engagement activities, enhancing job satisfaction and performance, which in turn boosts the company's competitiveness and social image [7]. - Yingke Medical received multiple awards in 2024 for its ESG initiatives, including the "Golden Antelope Award" for ESG innovation and the "Golden Dawn Award" for social responsibility [7].

证券代码：300677 证券简称：英科医疗 公告编号：2025-063 英科医疗科技股份有限公司 关于召开公司 2025 年第三次临时股东大会的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）已于 2025 年 司 2025 年第三次临时股东大会的通知》（公告编号：2025-060），为 保护投资者权益，方便公司股东行使股东大会表决权，现将有关事项 再次提示如下： 一、召开会议的基本情况 律、法规、部门规章、规范性文件及《英科医疗科技股份有限公司章 程》的规定。 （1）现场会议召开时间：2025 年 5 月 16 日（星期五）14:00 （2）网络投票时间：2025 年 5 月 16 日。其中，通过深圳证券交 易所交易系统进行网络投票的时间为 2025 年 5 月 16 日 9:15-9:25， 体时间为 2025 年 5 月 16 日 9:15-15:00。 司将通过深圳证券交易所交易系统和互联网投票系统 （http://wltp.cninfo.com.cn）向公司股东提供网络形式的投票平台，股 东可以在网络 ...

股东方面，截至2025年3月31日，英科医疗股东户数61786户，较上次增加1641户，户均持股市值35.28 万元，户均持股数量2.76万股。 英科医疗科技股份有限公司为综合型医疗护理产品供应商，主营业务涵盖医疗防护、康复护理、保健理 疗、检查耗材四大板块，主要产品包括一次性手套、轮椅、冷热敷、电极片等多种类型的护理产品。经 过多年的发展，公司已成为全球领先的医疗耗材供应商之一。 最新一期业绩显示，2025年一季报，公司实现营业收入24.94亿元，同比13.20%；净利润3.53亿元，同 比48.08%，销售毛利率24.16%。 5月12日，英科医疗今日收盘23.2元，上涨1.93%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到9.49倍，创24天以来新低，总市值149.92亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.84倍，行业中值36.59倍，英科医疗排 名第31位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)31英科医疗9.4910.230.84149.92亿行业平均 49.8445.684.61105.51亿行业中值36.5938.052.4346 ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-064 英科医疗科技股份有限公司 关于参加 2025 年山东辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，英科医疗科技股份有限公司 （以下简称"公司"）将参加由山东证监局、山东上市公司协会与深 圳市全景网络有限公司联合举办的"2025 年山东辖区上市公司投资 者网上集体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站（http://rs.p5w.net）；或关注微信公众号（名称：全景财经）； 或下载全景路演 APP，参与本次互动交流。活动时间为 2025 年 5 月 15 日（周四）15:00-16:30。届时公司高管将在线就公司 2024 年度业 绩、公司治理、发展战略、经营状况、融资计划、股权激励和可持续 发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资 者踊跃参与！ 特此公告！ 英科医疗科技股份有限公司 董 事 会 2025 年 5 月 13 日 ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-063 1、股东大会届次：2025 年第三次临时股东大会 2、召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召开符合有关法 律、法规、部门规章、规范性文件及《英科医疗科技股份有限公司章 程》的规定。 4、会议召开的日期、时间 （1）现场会议召开时间：2025 年 5 月 16 日（星期五）14:00 （2）网络投票时间：2025 年 5 月 16 日。其中，通过深圳证券交 易所交易系统进行网络投票的时间为 2025 年 5 月 16 日 9:15-9:25， 英科医疗科技股份有限公司 关于召开公司 2025 年第三次临时股东大会的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 29 日在巨潮资讯网（www.cninfo.com.cn）发布了《关于召开公 司 2025 年第三次临时股东大会的通知》（公告编号：2025-060），为 保护投资者权益，方便公司股东行使股东大会表决权，现将有关事项 再次提示如下： ...

Market Performance - The Shanghai Composite Index and Shenzhen Component Index experienced declines of 0.30% and 0.69% respectively on May 5, 2025, while the ChiNext Index and STAR Market 50 fell by 0.87% and 1.96% respectively [1] - Among 33 A-share companies in Zibo, 30 saw an increase, 1 remained flat, and 2 declined during the same period [1] Notable Stock Movements - Weiming Pharmaceutical (002581) achieved a remarkable 23.29% increase over five days, leading the gains [1] - Yahua Electronics (301337) and Jincheng Pharmaceutical (300233) also saw significant increases of 17.30% and 11.31% respectively [1] - On May 7, PEEK material concept stocks surged, with Zhongxin Fluorine Materials (002915) hitting the daily limit for the sixth time in nine days, and Kaisheng New Materials (301069) rising by 2.29% with a trading volume of 4.02 billion yuan [1] Company Announcements - Kehui Co., Ltd. announced a share repurchase plan with a budget between 9 million and 16 million yuan, with a maximum repurchase price of 17 yuan per share, aimed at employee stock ownership plans [1] Financial Results - Furuida (600223) reported a revenue of 526 million yuan in its cosmetics segment for Q1 2025, with a gross margin of 61.06% [3] - Qichang Tenda (002408) achieved total revenue of 5.618 billion yuan in Q1 2025, a year-on-year increase of 2.53%, but saw a significant drop in net profit by 83.18% to 5.4007 million yuan [3] - Xinhua Medical (600587) reported a total revenue of 2.308 billion yuan, down 8.74% year-on-year, with a net profit decline of 23.97% to 160 million yuan [3] - Bohui Paper (600966) reported a total revenue of 4.564 billion yuan, a 3.77% increase year-on-year, but a net profit decline of 46.91% to 53.3737 million yuan [3] Market Capitalization - In terms of market capitalization, Yingke Medical (300677) led with 14.708 billion yuan, followed closely by Shandong Pharmaceutical Glass (600529) at 14.626 billion yuan, and Qichang Tenda (002408) at 12.963 billion yuan [4]

Core Insights - The total revenue of 33 A-share listed companies in Zibo for 2024 is approximately 147.77 billion yuan, with 23 companies showing revenue growth compared to the previous year [1][2] - The total net profit for these companies is around 6.66 billion yuan, with 19 companies experiencing a year-on-year increase in net profit [1][8] Revenue Performance - 23 companies achieved positive revenue growth, while 10 companies reported declines [2] - Three companies surpassed the 10 billion yuan revenue mark: Qixiang Tengda (25.22 billion yuan), Bohui Paper (18.93 billion yuan), and Xinhua Medical (10.02 billion yuan) [2][4] - Qixiang Tengda remains the revenue leader despite a 6.31% decline in revenue [4] - Bohui Paper produced 4.53 million tons of paper, achieving a revenue of 18.93 billion yuan, a 1.27% increase [4] - Xinhua Medical's revenue increased slightly by 0.09%, with significant growth in its pharmaceutical equipment segment [4][5] Profitability Analysis - The total net profit of 33 companies is approximately 6.66 billion yuan, with notable profit leaders being Yingke Medical (1.47 billion yuan), Shandong Yaobang (943 million yuan), and Xinhua Medical (692 million yuan) [8][9] - Yingke Medical's net profit surged by 282.63%, marking it as the most profitable company [9][10] - 19 companies reported an increase in net profit, while 14 companies experienced declines [8][12] - Five companies saw net profit declines exceeding 50%, with Yahua Electronics reporting a significant loss of 26 million yuan [12][13] Notable Companies - Yingke Medical's production capacity utilization reached 100%, with a recovery in sales prices compared to 2023 [10] - Bohui Paper's strong production capacity contributed to its stable revenue growth [4] - Xinhua Medical is expanding its international presence with five overseas sales centers [5] - Blue Sail Medical, despite a revenue increase of 26.91%, reported a loss of 446 million yuan [16]

Core Viewpoint - In 2025, Yingke Medical Technology Co., Ltd. continues to show growth, with Q1 revenue reaching 2.494 billion yuan, a year-on-year increase of 13.2%, and net profit attributable to shareholders at 353 million yuan, up 48.08% [1] Group 1: Financial Performance - The company reported Q1 2025 revenue of 2.494 billion yuan, reflecting a 13.2% year-on-year growth [1] - Net profit for the same period was 353 million yuan, marking a significant increase of 48.08% [1] Group 2: Production Capacity and Market Trends - Yingke Medical's annual production capacity for disposable non-latex gloves has reached 87 billion units, with nitrile gloves accounting for 56 billion units and PVC gloves for 31 billion units, maintaining a product quality rate of over 99% [1] - The global market for disposable gloves is projected to reach 82.93 billion units in sales volume and 13.6 billion USD in revenue by 2025, with nitrile gloves gaining prominence in various sectors due to their safety and functionality [1] Group 3: Product Diversification and Market Strategy - The company is increasing investments in rehabilitation and other product areas, including wheelchairs and various medical supplies, driven by the growing demand from an aging population [2] - Yingke Medical is implementing a dual strategy of efficient supply chain management and penetration into emerging markets, establishing marketing service centers in Malaysia and Vietnam [2] - The company is enhancing its overseas supply chain and production capabilities to build a regional supply system that covers major markets, thereby improving risk resilience [2]